TSRI At The Forefront: Milestones in Medical Science

The human immune system sometimes misdirects its attacks, leading to allergies, autoimmune diseases like multiple sclerosis and rheumatoid arthritis, and rejection of transplant organs and therapeutic drugs. Current immune suppressants are either prohibitively expensive and take years to work or compromise the entire immune system.

But a team from The Scripps Research Institute (TSRI) led by James Paulson, chair of TSRI's Department of Cell and Molecular Biology, has demonstrated a new technique to treat hemophilia that may lead to a better way to selectively repress unwanted immune reactions without affecting the immune system as a whole.
The technique involves selective killing only of the B cells that react to the particular autoantigen.

No comments: